New Triple-Threat treatment tested for aggressive blood cancers
NCT ID NCT03862157
Summary
This study is testing a combination of three drugs—azacitidine, venetoclax, and pevonedistat—for adults newly diagnosed with certain high-risk blood cancers. These include acute myeloid leukemia (AML) that developed from other blood disorders or prior cancer treatment, as well as high-risk myelodysplastic syndrome (MDS). The first part of the study aims to find the safest and most effective dose of venetoclax when used with the other two drugs. The second part will see how well the combination works to control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.